Active Ingredient(s): Satralizumab
FDA Approved: * August 14, 2020
Pharm Company: * GENENTECH
Category: Immunosuppressive

Satralizumab, sold under the brand name Enspryng, is a humanized monoclonal antibody medication that is used for the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease.[5][6] The drug is being developed by Chugai Pharmaceutical, a subsidiary of Roche.[7] The most common side effects include the common cold (nasopharyngitis), headache, upper respiratory tract infection, inflammation of the lining of the stomach... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Enspryng 120 mg/ml Subcutaneous Injection, Solution
NDC: 50242-007
Genentech Inc.